» Articles » PMID: 32666104

Angiopoietin-1 Enhanced Myocyte Mitosis, Engraftment, and the Reparability of HiPSC-CMs for Treatment of Myocardial Infarction

Overview
Journal Cardiovasc Res
Date 2020 Jul 16
PMID 32666104
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: To examine whether transient over-expression of angiopoietin-1 (Ang-1) increases the potency of hiPSC-CMs for treatment of heart failure.

Methods And Results: Atrial hiPSC-CMs (hiPSC-aCMs) were differentiated from hiPSCs and purified by lactic acid and were transfected with Ang-1 (Ang-1-hiPSC-aCMs) plasmid using lipoSTEM. Ang-1 gene transfection efficiency was characterized in vitro. Gene transfected CMs (1×106) were seeded into a fibrin/thrombin patch and implanted on the rat-infarcted left ventricular (LV) anterior wall after myocardial infarction (MI). Echo function was determined at 1- and 6 weeks post-MI. Immunohistochemistry study was performed at 6 weeks post-MI. Ang-1 (20 and 40 ng/mL) protected hiPSC-aCMs from hypoxia through up-regulating pERK1/2 and inhibiting Bax protein expressions. Ang-1-hiPSC-aCMs transiently secreted Ang-1 protein up to 14 days, with peak level on day-2 post-transfection (24.39 ± 13.02 ng/mL) in vitro. Animal study showed that transplantation of Ang-1-hiPSC-aCM seeded patch more effectively limited rat heart apoptosis at 1 day post-MI as compared with LipoSTEM-Ang-1 or hiPSC-aCMs transplantation. Ang-1-hiPSC-aCMs transplantation induced host (rat) and donor (human) CM mitosis and arteriole formation, improved cell engraftment rate, more effectively limited LV dilation (EDV = 460.7 ± 96.1 μL and ESV = 219.8 ± 72.9 μL) and improved LV global pump function (EF = 53.1 ± 9%) as compared with the MI (EDV = 570.9 ± 91.8 μL, P = 0.033; ESV = 331.6 ± 71.2 μL, P = 0.011; EF = 42.3 ± 4.1%, P = 0.02) or the LipoSTEM-Ang-1 injected (EDV = 491.4 ± 100.4 μL, P = 0.854; ESV = 280.9 ± 71.5 μL, P = 0.287; EF = 43.2 ± 4.6, P = 0.039) or hiPSC-CM transplanted (EDV = 547.9 ± 55.5 μL, P = 0.095; ESV = 300.2 ± 88.4 μL, P = 0.075; EF = 46 ± 10.9%, P = 0.166) animal groups at 6 weeks post-MI and treatment.

Conclusion: Transient over-expression of Ang-1 enhanced hiPSC-aCM mitosis and engraftment and increased the reparability potency of hiPSC-aCMs for treatment of MI.

Citing Articles

Follistatin From hiPSC-Cardiomyocytes Promotes Myocyte Proliferation in Pigs With Postinfarction LV Remodeling.

Wei Y, Walcott G, Nguyen T, Geng X, Guragain B, Zhang H Circ Res. 2024; 136(2):161-176.

PMID: 39692006 PMC: 11747791. DOI: 10.1161/CIRCRESAHA.124.325562.


Dynamic three dimensional environment for efficient and large scale generation of smooth muscle cells from hiPSCs.

Green A, Wei Y, Warram J, Hartman Y, Geng X, Nguyen T Stem Cell Res Ther. 2024; 15(1):463.

PMID: 39627821 PMC: 11616106. DOI: 10.1186/s13287-024-04053-z.


IKKα-STAT3-S727 axis: a novel mechanism in DOX-induced cardiomyopathy.

Chen G, Yao Y, Liu Y, Zhang R, Wen C, Zhou Q Cell Mol Life Sci. 2024; 81(1):406.

PMID: 39287798 PMC: 11408453. DOI: 10.1007/s00018-024-05439-1.


Induced pluripotent stem cell therapies in heart failure treatment: a meta-analysis and systematic review.

Le D, Bui H, Vu Y, Vo Q Regen Med. 2024; 19(9-10):497-509.

PMID: 39263954 PMC: 11487948. DOI: 10.1080/17460751.2024.2393558.


Doxycycline-Mediated Control of Cyclin D2 Overexpression in Human-Induced Pluripotent Stem Cells.

Qiao A, Wei Y, Liu Y, Kahn-Krell A, Ye L, Nguyen T Int J Mol Sci. 2024; 25(16).

PMID: 39201401 PMC: 11354523. DOI: 10.3390/ijms25168714.